Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innocan Pharma Corp (OP: INNPF )

0.1464 UNCHANGED
Last Price Updated: 9:38 AM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Innocan Pharma Corp

< Previous 1 2 Next >
CBD-Focused Innocan Pharma Achieves 4X Revenue Growth In Q1, Hits $6.8M Mark
Innocan Pharma's Q1 2024 revenue surged 334% to $6.8M, driven by strong sales growth from BI Sky Global. Read about financial performance. 
Via Benzinga
This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration... 
Via Benzinga
Exposures Product Safety
534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations
Innocan Pharma's 2023 earnings report: Revenue soars 534%, operating loss down 61%, $1.5M capital raise. CEO shares strategic vision. 
Via Benzinga
CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval
Cannabinoid-focused pharmaceutical company Innocan Pharma Corp expects preliminary revenues of $4.89m in Q4 of fiscal 2023, representing a YoY increase of 331%. It said preliminary revenues are... 
Via Benzinga
Exposures Product Safety
4 CBD Stocks in the Canadian Capital Market
Photo by 
Via Benzinga
Key Leadership Changes In Cannabis You Should Know About As We Head Into 2024
This month, the Indigenous Cannabis Industry Association held its first Indigenous Cannabis Regulators roundtable, bringing together Indigenous Cannabis Regulators from Tribal Nations and... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
More Cannabis Funding For FDA And Product Expansion: How This Pharma Tech Company Is Doing It
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) has closed the second and final tranche of its previously announced private placement offering of its units. 
Via Benzinga
Topics Cannabis
Exposures Cannabis Product Safety
CBD-Focused Pharma Co. Seeks Funding To Revolutionize Healthcare
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) has entered into an agreement with Research Capital Corporation as the sole agent and sole book-runner on a "best efforts" agency basis... 
Via Benzinga
Innocan Pharma's Q2 2023 Reports Gross Profit Growth Driven By Robust Subsidiary Sales
Innocan Pharma Corporation (CSE: INNO)(FSE: IP4) (OTC: INNPF), a pharmaceutical technology firm specializing in innovative drug delivery platforms, 
Via Benzinga
Cannabis Stock Gainers And Losers From August 25, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Innocan Pharma Secures $1.4M Via Private Placement
Innocan Pharma Corporation (OTC: INNPF) (CSE:INNO) (FSE:IP4) has closed a non-brokered private placement offering of 8.4 million units of Innocan at a price of CA$0.23 per unit 
Via Benzinga
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Innocan Pharma To Secure Up To $3M Via Private Placement Of Units At A 9% Prime Above Share Price
Innocan Pharma Corporation (OTCQB: INNPF) (CSE:INNO) (FSE:IP4) intends to complete a non-brokered private placement of up to 17.22 million units of the company at a price of CA$0.23 per unit fo 
Via Benzinga
Bullish Thursday For Marijuana Stocks - EVIO, Tetra Bio Pharma Among Top Gainers
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Movers For July 21, 2023
Via Benzinga
Cannabis Stock Gainers And Losers From August 14, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Innocan Pharma Q1 Revenue Grows 500%, Here Is What You Need To Know
Innocan Pharma Corporation (OTCQB: INNPF) (CSE:INNO) (FSE:IP4) released its financial results for the three months ended March 31, 2023, revealing revenue of $1.6 million, an increase of 500%, 
Via Benzinga
Cannabis Stock Gainers And Losers From August 11, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Innocan Pharma FY22 Revenue Grows 1205% To $2.6M, Here Is What You Need To Know
Innocan Pharma Corporation (OTCQB: INNPF) (CSE:INNO) (FSE:IP4) released its audited financial results for the year ended December 31,2022, revealing revenue of $2.6 million, an increase of 1205% from... 
Via Benzinga
Can Liposomal CBD Injection Help Dogs With Polyarthritis? Innocan Pharma Reports Clinical Success
Innocan Pharma Corporation (OTCQB: INNPF) (CSE:INNO) (FSE:IP4) reported clinical success in its Canine (dogs) Compassionate Care Trial, resulting in improving walking abilities and significant decrease... 
Via Benzinga
Innocan Pharma Q3 Revenue Grows 700% YoY, Here Is What You Need To Know
Innocan Pharma Corporation (OTCQB: INNPF) (CSE:INNO) (FSE:IP4) released its financial results for the three and nine months ended September 30, 2022, revealing Q3 revenue of $1.42 million, a 700% 
Via Benzinga
Innocan Pharma Provides an Operational Update
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 21, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB:... 
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment
A 4-year-old intact male border collie dog with a body weight of 22 kg was suffering from refractory idiopathic (drug-resistant)... 
Via Newsfile
Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 6, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF)... 
Via Newsfile
Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 3, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF)... 
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Innocan Pharma Received Proceeds of CAD $8.2M from the Exercise of Warrants since January 1, 2021
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 27, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF)... 
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Innocan Exercises Option to Enter into a Research and License Agreement with Ramot the Commercial company of the Tel Aviv University
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 18, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF)... 
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Innocan Engages Ayurcann Inc. to Manufacture and Distribute Innocan's CBD Topicals in Canada
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 11, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF)... 
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Innocan Pharma Updates its Progress in the Pre-Clinical Studies of its CBD-Loaded Liposome Platform (LPT)
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 3, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF)... 
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Innocan Pharma Announces the Filing of a Patent Application for the Treatment and Prevention of Hair Loss
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 28, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB:... 
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.